Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Oxford University’s Medical Sciences Business Development & Partnering team reflect on 2018 and look forward to 2019

The Business Development & Partnering team standing together surrounded by festive Christmas decoration

2018 was a landmark year for the Divisional Business Development and Partnering Team. In addition to strengthening our research alliances with UCB, Novo Nordisk, Celgene, Pfizer and Bayer, we also saw some important strategic developments. We were delighted to welcome Novo Nordisk to Oxford in the summer, with the opening of the Novo Nordisk Oxford Research Centre based on the Old Road Campus which will strengthen our research partnership. The summer also saw the opening of the BioEscalator, a hub for new and developing life science innovations.

We were thrilled to learn that Innovate UK and industry are to invest more than £17.5 million in the University of Oxford to develop artificial intelligence (AI) healthcare applications. Funding will be provided through the Government’s Industrial Strategy Challenge Fund by as part of a £50 million investment to establish a network of digital pathology, imaging and AI centres, to drive innovation in the use of AI for improved diagnosis and delivery of precision treatments.

We have continued to deliver a range of events to engage our research community with industry, including the 2018 AIMday in Biomedical Imaging which was a huge success and we hope to repeat this in 2019 with a new AIMday in Advanced Therapies and Regenerative Medicine.

More recently, the Oxford MIT Healthcare Technologies of the Future Conference saw the University of Oxford and MIT come together to strengthen and share our industry networks and highlight some of our spin outs.

We are delighted to have developed, delivered and supported so many alliances, collaborations, opportunities and events in 2018 and look forward to a successful and fruitful 2019.

Find out more about the Business Development Team

Similar stories

Young lives under pressure as global crises hits mental health and well-being – report

The well-being and mental health of young people in low - and middle - income countries have been dramatically affected by the series of crises hitting the world. As the international community continues to struggle with the impact of COVID-19, conflict and climate change, the latest report from the Young Lives project shows a long-running upward trend in young people’s well-being has been sharply reversed alongside widespread anxiety and depression. Young people are less confident about their futures for the first time in the 20-year study.

Bacterial infections linked to one in eight global deaths, according to GRAM study

Data showing 7.7 million deaths from 33 bacterial infections can guide measures to strengthen health systems, particularly in low-income settings

New tool aims to make bowel cancer treatments more effective

The Leedham Lab in Nuffield Department of Medicine (NDM) has been awarded over £2M from Cancer Research UK to develop a new tool that could help guide how bowel cancer patients are treated in the future.

Doug Higgs awarded the 2023 Genetics Society Medal

The award recognises Radcliffe Department of Medicine's Professor Higgs major contribution to our understanding of how mammalian genes are switched on and off, and using haematopoiesis as a model to understand how genes function.

First evidence drug resistant bacteria can travel from gut to lung, increasing infection risks

A new Oxford University study released during World Antimicrobial Awareness Week has significant findings on how antimicrobial resistance (AMR) arises and persists. The results, published today in Nature Communications, provide the first direct evidence of AMR bacteria migrating from a patient’s gut microbiome to the lungs, increasing the risk of deadly infections.